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Abstract
Background: We aimed to assess outcomes of patients with anal cancer who underwent intensity-modulated
radiotherapy (IMRT) and received less than 1.80 Gy/day.
Methods: We retrospectively reviewed our experience using a low fractional dose (< 1.80 Gy) of IMRT to elective
nodal areas for patients receiving chemoradiotherapy for anal cancer. Three-year freedom from any disease relapse
and overall survival were estimated using Kaplan-Meier curves. We documented the daily dose that was delivered
to clinically uninvolved regions and to areas of gross disease. Incidence of regional failures in high (≥ 1.80 Gy) and
low (< 1.80 Gy) daily dose regions was assessed.
Results: Thirty-four consecutive patients (median age, 59 years) received IMRT from June 2005 through January 2009.
Median follow-up duration was 22 months. Twenty-eight patients had T1 or T2 disease and 6 had T3 or T4 disease.
Fourteen patients had nodal metastases. Median treatment dose was 50.40 Gy (range, 48.60-57.60 Gy) in 25 to 32
fractions. The range of fractional doses to clinically negative volumes was 1.28 to 1.80 Gy. Seventeen patients (50%)
received a fractional dose of less than 1.60 Gy, 13 (38%) received less than 1.50 Gy, and 9 (26%) received less than 1.40
Gy to at least a portion of the clinically negative volume. Three-year freedom from relapse was 80%, and 3-year overall
survival was 87%. No patient had treatment failure in the clinically negative volume that received a low daily dose.
Conclusions: Our data support using doses between 1.50 and 1.80 Gy/day to clinically uninvolved regions.
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Introduction
Fluorouracil (FU) and mitomycin C (MMC) combined
with radiotherapy is the standard treatment for squa-
mous cell carcinoma arising in the anal canal (1-4). Trials
of conventional radiotherapy techniques have shown sig-
nificant toxicity (1), and interest has focused on inten-
sity-modulated radiotherapy (IMRT) in this setting, with
t h eh o p eo fd e c r e a s i n gs e v e r et o x i c i t y .T h eR a d i a t i o n
Therapy Oncology Group (RTOG) has developed an
IMRT protocol that has been tested in a multi-institu-
tional study (5). The protocol uses a daily fraction dose
that varies according to the specific target volume. Such
a technique allows gross disease and elective areas to
receive different total doses while the number of fractions
remains the same. Under certain conditions, elective
regions could receive a fractional dose as low as 1.50 Gy
per day. Historically, anal cancer has been treated with
doses of at least 1.80 Gy per day, with a shrinking-field
technique over the course of treatment. Data on doses
less than 1.80 Gy per day are lacking. At our institution,
use of such lower doses in the treatment of anal cancer is
common when using IMRT. This study was undertaken
to review our experience of low-dose IMRT (< 1.80 Gy
per day) in the treatment of anal cancer and to determine
the rate of regional failures with this treatment regimen.
Methods and Materials
This study was approved by the Mayo Clinic Institu-
tional Review Board. We reviewed all patients with
squamous cell carcinoma of the anus who received
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January 2009 at Mayo Clinic, Rochester, Minnesota. All
living patients authorized review of their medical record
in accordance with Minnesota state law. Data on patient
and tumor characteristics, details about radiotherapy,
and outcomes of disease control and survival were
obtained from the medical record. All cancers were eval-
uated (assigned a TNM stage) according to the American
Joint Committee on Cancer Staging Manual, seventh
edition (6). Regional failures were recorded, along with
the dose received during IMRT. Follow-up primarily con-
sisted of a physical examination, with imaging studies
performed at the discretion of the supervising physician.
Biopsies were not routinely performed if physical exami-
nation findings were favorable.
Statistical Analysis
The Kaplan-Meier method was used to calculate and
estimate rates of overall survival and freedom from any
disease relapse. Data were analyzed using JMP software
(version 8.0; SAS Institute, Cary, North Carolina).
Results
Patient and Tumor Characteristics
We identified 34 consecutively treated patients who
received definitive IMRT and chemotherapy (FU alone
[n = 1] or a combination of FU and MMC [n = 33]).
Patient characteristics are displayed in Table 1. Median
age was 59 years. Twenty-eight patients (82%) had T1
or T2 disease, and 6 (18%) had T3 or T4 disease. Four-
teen patients (41%) had nodal disease. The median dura-
tion of follow-up was 22 months.
Radiotherapy
Details of radiotherapy are shown in additional file 1
Tables 2 and 3, stratified by nodal disease status (stage
N0 vs N+ disease). Radiation was delivered with 6-MV
photon beams to 11 fields (n = 1) or to 9 fields (n =
33). It was common to treat the upper pelvis with a
lower dose than the lower pelvis. (Upper and lower pel-
vis volumes typically were delineated around the bottom
of the sacroiliac joints.) The treating clinician individua-
lized gross tumor volumes, clinical target volumes, and
planning target volume expansions for each patient. A
simultaneous integrated boost (SIB) technique was used
to treat the gross tumor volume and elective areas in a
single treatment plan (ie, applying different doses per
fraction to different target volumes). Use of low frac-
tional doses of radiation was common. Doses ranged
from 48.60 to 57.60 Gy (median, 50.40 Gy) in 25 to 32
fractions.
Gross disease was treated with a daily fraction of 1.80
to 2.25 Gy. The gross tumor volume was commonly
treated with a margin that varied according to the dis-
cretion of the treating clinician but would often include
immediately adjacent lymph node tissues. Doses to elec-
tively covered areas that were outside those margins are
specified in additional file 1 Tables 2 and 3.
The range of doses to clinically negative volumes was
1.28 to 1.80 Gy per day. All patients received less than
1.80 Gy per fraction to some portion of the electively
covered volume. Seventeen patients (50%) received a
fractional dose less than 1.60 Gy, 13 (38%) received less
than 1.50 Gy, and 9 (26%) received less than 1.40 Gy to
at least a portion of the clinically negative volume. Posi-
tive nodes received a median fractional dose of 1.93 Gy
(range, 1.80-2.25 Gy).
Disease Control and Overall Survival
The 3-year freedom from any disease relapse was 80%
(Figure 1). Three patients had a local failure, one patient
had a regional lymph node failure, and 4 had cancer
recur at distant sites (one had a distal failure 3 months
after a local failure). The patient with the regional fail-
ure had progression at a site of gross nodal disease that
was treated with a dose of 56.25 Gy in 25 fractions (2.25
Gy per day). No treatment failures were observed in the
target volumes that received less than 1.80 Gy per day
(100% regional control in low-dose areas).
Three patients died during the follow-up period. One
patient died of cardiac arrest 6 months after the diagnosis
of anal cancer; the patient was disease free at the time of
death. The second patient died of sepsis associated with
metastatic anal cancer 10 months after diagnosis. The
third patient was a 79-year-old woman with a history of
congestive heart failure and chronic obstructive pulmon-
ary disease; she died after 26 months of follow-up.
Table 1 Patient Characteristics (N = 34)
Characteristic Value
Age, median (range), y 59 (46-85)
IMRT dose, median (range), Gy 50.40 (48.60-57.60)
Chemotherapy, No.












Abbreviations: FU, fluorouracil; IMRT, intensity-
modulated radiotherapy; MMC, mitomycin C.
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case, she did not have evidence of recurrent cancer dur-
ing the follow-up period. The remaining 31 patients were
alive at the time of manuscript preparation, with a med-
ian survival of 23 months. The estimated survival at 3
years was 87% for the entire group.
Discussion
IMRT for anal cancer is currently under investigation in
a multi-institutional study. Using IMRT with SIB to treat
different targets with different daily doses often results in
some areas receiving less than the conventional fractional
doses of radiation (ie, < 1.80 Gy). This technique has
some treatment benefits. Multiple IMRT plans could be
used to allow no change in fractional dose during the
treatment period, but this requires additional planning
and quality assurance and also extends the treatment
time. Increased treatment times may be associated with
poor disease control (7-13). Use of IMRT to deliver an
SIB has the advantage of being able to deliver the radia-
tion in a shorter time. However, this necessitates varying
the fractional dose, and thus clinically negative areas may
be treated with lower daily doses than what has typically
been administered in anal cancer clinical trials. Data on
the biologic effects and clinical outcomes of such low
doses are lacking.
Historically, anal cancers were treated with surgical
therapy involving an abdominoperineal resection. Inter-
est in improving outcomes for these patients led to the
discovery that these tumors responded to chemotherapy
and radiotherapy. Such therapy, delivered in a neoadju-
vant fashion, decreased the failure rate compared with
that of surgery alone (14,15). This ultimately led to a
primary approach of chemoradiotherapy, obviating the
need for surgery for patients with a complete response
and negative biopsy findings (16).
Radiotherapy and concurrent FU and MMC is the
current standard of care and allows many patients to
avoid having a colostomy. Several prospective trials on
chemoradiotherapy have been performed in the study of
this disease. Although there has been some variation in
technique, an overview of these trials shows that they
generally have used doses of at least 1.80 Gy per day.
Phase 3 trials performed by the United Kingdom Coordi-
nating Committee on Cancer Research (UKCCCR) and
the European Organization for Research and Treatment
of Cancer (EORTC) demonstrated that chemoradiother-
apy with these agents was superior to radiotherapy alone
in terms of local control and the ultimate need for a
colostomy (2,4). In the UKCCCR trial, treatment involved
a technique of opposed anterior and posterior fields to
treat the central axis with a dose of 45 Gy in 20 to 25
fractions over 4 to 5 weeks. Patients with less than 50%
response were treated surgically, and all others were
recommended to receive a boost (15 Gy in 6 fractions, by
electrons, photons, or an interstitial implant) over 2 to 3
days. In the EORTC trial, initial fields (3- or 4-field tech-
nique) were treated with 45 Gy (1.80 Gy per day) over 5
weeks. After a 6-week break, patients with a complete
response then received a further boost of 15 Gy, whereas
those with a partial response received 20 Gy. Other trials
have examined the optimal chemotherapy to be delivered
with radiotherapy in the definitive treatment of anal can-
cer. Continuous infusion of FU alone (1,000 mg/m
2 per
day over 96 hours, starting days 1 and 29 of radiotherapy)
was inferior to chemotherapy with MMC (10 mg/m
2 on
days 1 and 29) in a phase 3 trial performed by the RTOG
and Eastern Cooperative Oncology Group (trial RTOG
87-04/ECOG 1289) (3). The first 45 Gy of radiotherapy
were concomitant with the first 2 cycles of chemotherapy
and used parallel opposed fields and a daily fraction of
1.80 Gy. After 30.6 Gy was administered, the top field
border was reduced from the interspace between L4 and
L5 to the bottom of the sacroiliac joints. This field was
continued until a dose of 36 Gy was administerd. Finally,
a boost field to the tumor alone was used until a total
dose of 45 Gy was achieved.
If a tumor was still palpable immediately after the
initial 45 Gy, the patient had a boost treatment with
another 5.4 Gy. For patients with N1 disease, both ingu-
inal regions were initially treated with a dose of 50.40 Gy
at a prescription depth of 3 cm. After 4 to 6 weeks,
patients were assessed by a biopsy; if results were posi-
tive, they received further therapy. For patients with
biopsy results showing residual primary disease, salvage
therapy consisted of 9 Gy in 5 fractions (delivered with
electrons or photons) and the same regimen of FU plus
cisplatin (100 mg/m
2) on day 2 of radiotherapy. Patients
with palpable inguinal disease after administration of 45
to 50.4 Gy received an additional 9 Gy.
Figure 1 Estimated Rate of Freedom From Any Disease Relapse
in All Patients. The rate at 3 years was 80%.
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for the MMC component of therapy. Patients were ran-
domized to 1 of 2 treatment arms: 1) concurrent FU,
MMC, and radiotherapy; or 2) neoadjuvant cisplatin and
FU alone, followed by concurrent chemoradiotherapy
with cisplatin and FU. The treatment arm with MMC
and FU had a significantly reduced colostomy rate. The
radiotherapy was also administered with shrinking fields;
after 30.6 Gy was administered, the superior border was
moved down from L5 and S1 to the bottom of the sacroi-
liac joints, and a minimum of 14.4 Gy of additional radia-
tion was administered to the tumor (all at 1.80 Gy per
day). Node-negative patients received 36 Gy to inguinal
regions. Certain patients (stage T3 or T4, node positive,
or N2 with residual disease) were treated with a boost of
10 to 14 Gy at 2 Gy per fraction, for a total tumor dose
of 55 to 59 Gy.
A second phase 3 trial, conducted in the United King-
dom, examined outcomes after replacing MMC with cis-
platin that was administered concurrently (no initial gap)
with a radiotherapy dose of 50.4 Gy (17). This trial showed
no significant improvement in complete response rate
with concurrent cisplatin (95%) compared with MMC
(94%), and the need for a colostomy was similar between
g r o u p s .C u r r e n t l y ,r a d i o t h e r apy delivered concurrently
with FU and MMC remains the standard of care for squa-
mous cell carcinoma of the anal canal.
The RTOG initiated a multi-institutional effort to pro-
spectively treat patients with IMRT-based chemora-
diotherapy (RTOG 0529) (5). In this protocol, patients
received IMRT with SIB to treat the elective areas and
gross disease in the same number of fractions. IMRT was
able to significantly reduce the grade 2+ dermatologic and
grade 3+ gastrointestinal/genitourinary events compared
with the results of the RTOG 98-11 trial. Fractional doses
varied by the clinical situation but were as low as 1.5 Gy
per day to clinically negative areas.
Our data indicate that a low dose per fraction when
treating with an SIB technique may be effective for clini-
cally negative areas. It was common to treat at least a
portion of the elective areas with less than 1.80 Gy per
day. We observed only one regional failure that occurred
a tt h es i t eo fag r o s s l yp o s i t i v en o d et h a tr e c e i v e dad o s e
of 56.25 Gy (2.25 Gy per day). No patients in our series
had treatment failure within the elective, low-dose
volume. Kachnic et al (18) reported results from several
centers in Boston using an IMRT technique that com-
monly treated elective nodal areas with doses as low as
1.5 Gy per fraction. With a median follow-up of 24
months, these authors noted a 2-year local control rate of
95%, and only 2 of 43 patients had a pelvic recurrence. In
addition, trial RTOG-0529 used a similar technique for
treating patients by using IMRT to deliver a low daily
dose to elective areas. Preliminary 2-year results have
been reported (19), and the locoregional failure rate at
2 years was 20%. Long-term results are not yet available
to assess the effectiveness of the approach in a multi-
institutional setting. The results presented here add to
the growing body of data supporting the use of IMRT
with SIB for anal cancer. Regional control was excellent,
despite the common use of low doses per fraction.
Limitations of our data include the retrospective nat-
ure of this study. In addition, no standard method was
used to prescribe radiotherapy. In addition, the relatively
small size (34 patients) and short follow-up (22 months)
in this report should be noted. It was common for
patients to receive a low fractional dose to at least a
portion of the elective volume; however, specific dosages
to certain volumes were individualized according to the
judgment of each radiation oncologist. All patients in
this study received concurrent chemotherapy. We do
not know whether the same low rate of regional failure
would have been observed if such radiosensitizing agents
were not used.
In conclusion, our results indicate that low fractional
doses of radiation may be appropriate when using IMRT
for squamous cell carcinoma of the anus along with con-
current chemotherapy. A daily dose between 1.50 and
1.80 Gy per day to clinically negative areas, prescribed
according to the RTOG technique, may be appropriate in
certain clinical situations. No treatment failures were
noted in the low-dose prescription volumes, despite the
frequent use of fractional doses less than 1.80 Gy.
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